Post-traumatic Stress Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Post-traumatic Stress Disorder (PTSD) Treatment Landscape

The PTSD treatment market is extremely fragmented, with both small enterprises and large companies in competition. To treat PTSD symptoms, pharmaceutical firms are developing and marketing both new and well-known drugs, like anxiolytics and antidepressants. The market is competitive and dynamic, with a constant focus on improving patient outcomes and innovation.

Some of the prominent players include:

Jazz Pharmaceuticals plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Bionomics Limited
Merck KGaA
Pfizer Inc.
Aurobindo Pharma Limited
GlaxoSmithKline plc (GSK plc)
Viatris Inc.
Jubilant Pharmova Ltd.
H. Lundbeck A/S
Camber Pharmaceuticals, Inc.

Browse Key Market Insights with Data Illustration:

Post-traumatic Stress Disorder (PTSD) Treatment Market Report 2037

In the News

In July 2024, Bionomics Limited, a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, announced the start of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder (SAD).
In November 2021, Camber Pharmaceuticals announced the addition of Sertraline Hydrochloride Tablets to their current portfolio, which are the generic form of Zoloft. Sertraline Hydrochloride Tablets are prescribed to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD).